Graham Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Graham Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-101,051	Closed	-$7.73M	–	1177
2025 Q4	$7.73M	Sell	101,051 -177,077	-64%	-$11.6M	0.19%	78
2025 Q3	$14.4M	Buy	278,128 +253,269	+1,019%	+$12.4M	0.23%	46
2025 Q2	$1.07M	Buy	+24,859	New	+$904K	0.02%	563
2025 Q1	–	Sell	-4,725	Closed	-$130K	–	1293
2024 Q4	$130K	Sell	4,725 -27,696	-85%	-$716K	﹤0.01%	1133
2024 Q3	$825K	Buy	32,421 +15,712	+94%	+$412K	0.01%	509
2024 Q2	$423K	Buy	+16,709	New	+$457K	0.01%	633
2024 Q1	–	Sell	-1,079	Closed	-$36.7K	–	1062
2023 Q4	$43.6K	Buy	+1,079	New	+$32.4K	﹤0.01%	946
2022 Q4	–	Sell	-603,126	Closed	-$6M	–	1054
2022 Q3	$6M	Buy	603,126 +172,855	+40%	+$1.8M	0.24%	46
2022 Q2	$3.91M	Sell	430,271 -113,941	-21%	-$953K	0.16%	82
2022 Q1	$5.52M	Buy	+544,212	New	+$5.59M	0.19%	58

Other funds holding BBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Graham Capital Management's BBIO Position: Q1 2026 in Review

Graham Capital Management sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 101,051 shares — an estimated $7.73M sold.

Graham Capital Management first reported a position in BBIO in Q1 2022 and held it in 10 quarters. The position peaked at $14.4M in Q3 2025. 460 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Graham Capital Management reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
Graham Capital Management sold 101,051 BridgeBio Pharma shares in Q1 2026, an estimated $7.73M.
Graham Capital Management first reported a position in BridgeBio Pharma in Q1 2022 and held it in 10 quarters.
Graham Capital Management's BridgeBio Pharma position peaked at $14.4M in Q3 2025.
460 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.